Literature DB >> 20864339

Antidotes to anthrax lethal factor intoxication. Part 1: Discovery of potent lethal factor inhibitors with in vivo efficacy.

Guan-Sheng Jiao1, Seongjin Kim, Mahtab Moayeri, Lynne Cregar-Hernandez, Linda McKasson, Stephen A Margosiak, Stephen H Leppla, Alan T Johnson.   

Abstract

Sub-nanomolar small molecule inhibitors of anthrax lethal factor have been identified using SAR and Merck L915 (4) as a model compound. One of these compounds (16) provided 100% protection in a rat lethal toxin model of anthrax disease.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20864339      PMCID： PMC2965585          DOI： 10.1016/j.bmcl.2010.08.058

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN： 0960-894X            Impact factor:   2.823


  10 in total

1.  The discovery of a potent and selective lethal factor inhibitor for adjunct therapy of anthrax infection.

Authors:  Yusheng Xiong; Judyann Wiltsie; Andrea Woods; Jian Guo; James V Pivnichny; Wei Tang; Alka Bansal; Richard T Cummings; Barry R Cunningham; Arthur M Friedlander; Cameron M Douglas; Scott P Salowe; Dennis M Zaller; Edward M Scolnick; Dennis M Schmatz; Kenneth Bartizal; Jeffrey D Hermes; Malcolm MacCoss; Kevin T Chapman
Journal:  Bioorg Med Chem Lett       Date:  2005-12-09       Impact factor: 2.823

2.  Novel small-molecule inhibitors of anthrax lethal factor identified by high-throughput screening.

Authors:  Igor A Schepetkin; Andrei I Khlebnikov; Liliya N Kirpotina; Mark T Quinn
Journal:  J Med Chem       Date:  2006-08-24       Impact factor: 7.446

3.  Anthrax lethal factor inhibition.

Authors:  W L Shoop; Y Xiong; J Wiltsie; A Woods; J Guo; J V Pivnichny; T Felcetto; B F Michael; A Bansal; R T Cummings; B R Cunningham; A M Friedlander; C M Douglas; S B Patel; D Wisniewski; G Scapin; S P Salowe; D M Zaller; K T Chapman; E M Scolnick; D M Schmatz; K Bartizal; M MacCoss; J D Hermes
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-23       Impact factor: 11.205

4.  Enantioselective synthesis of (+)-cryptophycin 52 (LY355703), a potent antimitotic antitumor agent.

Authors:  Arun K Ghosh; Lisa Swanson
Journal:  J Org Chem       Date:  2003-12-12       Impact factor: 4.354

Review 5.  Discovery and development of anthrax lethal factor metalloproteinase inhibitors.

Authors:  Benjamin E Turk
Journal:  Curr Pharm Biotechnol       Date:  2008-02       Impact factor: 2.837

6.  Anthrax toxin: causative agent in the death of rhesus monkeys.

Authors:  F KLEIN; D R HODGES; B G MAHLANDT; W I JONES; B W HAINES; R E LINCOLN
Journal:  Science       Date:  1962-12-21       Impact factor: 47.728

Review 7.  Cellular and systemic effects of anthrax lethal toxin and edema toxin.

Authors:  Mahtab Moayeri; Stephen H Leppla
Journal:  Mol Aspects Med       Date:  2009-07-26

8.  Contribution of individual toxin components to virulence of Bacillus anthracis.

Authors:  C Pezard; P Berche; M Mock
Journal:  Infect Immun       Date:  1991-10       Impact factor: 3.441

9.  Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States.

Authors:  J A Jernigan; D S Stephens; D A Ashford; C Omenaca; M S Topiel; M Galbraith; M Tapper; T L Fisk; S Zaki; T Popovic; R F Meyer; C P Quinn; S A Harper; S K Fridkin; J J Sejvar; C W Shepard; M McConnell; J Guarner; W J Shieh; J M Malecki; J L Gerberding; J M Hughes; B A Perkins
Journal:  Emerg Infect Dis       Date:  2001 Nov-Dec       Impact factor: 6.883

10.  Role of N-terminal amino acids in the potency of anthrax lethal factor.

Authors:  Pradeep K Gupta; Mahtab Moayeri; Devorah Crown; Rasem J Fattah; Stephen H Leppla
Journal:  PLoS One       Date:  2008-09-03       Impact factor: 3.240
  10 in total
  9 in total

Review 1.  Targeting Metalloenzymes for Therapeutic Intervention.

Authors:  Allie Y Chen; Rebecca N Adamek; Benjamin L Dick; Cy V Credille; Christine N Morrison; Seth M Cohen
Journal:  Chem Rev       Date:  2018-09-07       Impact factor: 60.622

Review 2.  Designing inhibitors of anthrax toxin.

Authors:  Ekaterina M Nestorovich; Sergey M Bezrukov
Journal:  Expert Opin Drug Discov       Date:  2014-01-22       Impact factor: 6.098

Review 3.  An overview of investigational toxin-directed therapies for the adjunctive management of Bacillus anthracis infection and sepsis.

Authors:  Lernik Ohanjanian; Kenneth E Remy; Yan Li; Xizhong Cui; Peter Q Eichacker
Journal:  Expert Opin Investig Drugs       Date:  2015-04-28       Impact factor: 6.206

4.  Antidotes to anthrax lethal factor intoxication. Part 2: structural modifications leading to improved in vivo efficacy.

Authors:  Seongjin Kim; Guan-Sheng Jiao; Mahtab Moayeri; Devorah Crown; Lynne Cregar-Hernandez; Linda McKasson; Stephen A Margosiak; Stephen H Leppla; Alan T Johnson
Journal:  Bioorg Med Chem Lett       Date:  2011-02-18       Impact factor: 2.823

5.  Development of a comprehensive, validated pharmacophore hypothesis for anthrax toxin lethal factor (LF) inhibitors using genetic algorithms, Pareto scoring, and structural biology.

Authors:  Ting-Lan Chiu; Elizabeth A Amin
Journal:  J Chem Inf Model       Date:  2012-06-25       Impact factor: 4.956

6.  Highly predictive support vector machine (SVM) models for anthrax toxin lethal factor (LF) inhibitors.

Authors:  Xia Zhang; Elizabeth Ambrose Amin
Journal:  J Mol Graph Model       Date:  2015-11-17       Impact factor: 2.518

7.  Small-molecule inhibitors of lethal factor protease activity protect against anthrax infection.

Authors:  Mahtab Moayeri; Devorah Crown; Guan-Sheng Jiao; Seongjin Kim; Alan Johnson; Clinton Leysath; Stephen H Leppla
Journal:  Antimicrob Agents Chemother       Date:  2013-06-17       Impact factor: 5.191

Review 8.  Inhibitors of the Metalloproteinase Anthrax Lethal Factor.

Authors:  Allison B Goldberg; Benjamin E Turk
Journal:  Curr Top Med Chem       Date:  2016       Impact factor: 3.295

9.  Mapping the epitopes of a neutralizing antibody fragment directed against the lethal factor of Bacillus anthracis and cross-reacting with the homologous edema factor.

Authors:  Philippe Thullier; Arnaud Avril; Jacques Mathieu; Christian K Behrens; Jean-Luc Pellequer; Thibaut Pelat
Journal:  PLoS One       Date:  2013-05-31       Impact factor: 3.240
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.